HUTCHMED Highlights SAVANNAH Trial Data Of Savolitinib Combo In Lung Cancer Setting
HUTCHMED (China) Limited (NASDAQ:HCM) announced the first presentation of results from the ongoing SAVANNAH Phase 2 trial at the upcoming World…
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
All news is property of their respective owners.
